Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × tazemetostat × Other hematologic neoplasm × Clear all

Phase

Phase 1 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6 Genitourinary 3 Sarcoma 2 Thoracic 1 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Dermatologic 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 101 Cyclophosphamide 95 venetoclax 84 fludarabine 75 Azacitidine 73 fludarabine phosphate 64 Rituximab 51 Filgrastim 39 Peripheral Blood Stem Cell Transplantation 36 Methotrexate 35 Decitabine 31 Dexamethasone 30 Busulfan 29 Etoposide 27 Mycophenolic Acid 26 Whole-Body Irradiation 25 Tacrolimus 25 Lenalidomide 24 Cyclosporine 24 Vincristine 23 Idarubicin 23 Granulocyte Colony-Stimulating Factor 23 Mitoxantrone 22 Melphalan 22 Clofarabine 21 Bortezomib 20 Alemtuzumab 19 Imatinib Mesylate 17 ruxolitinib 16 ibrutinib 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05205252 2023-08-15

ARIA

Ipsen

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡